Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Bioniz	Registered Direct Offerings	Common Stock	Common Stock Bioniz	Common Stock Registered Direct Offerings	Additional Paid-in Capital	Additional Paid-in Capital Bioniz	Additional Paid-in Capital Registered Direct Offerings	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2020	$ 69,854			$ 2			$ 141,074			$ (297)	$ (70,925)
Balance, Shares at Dec. 31, 2020				24,753,102
Issuance of common stock under registered direct offering, net of offering costs			$ 29,909						$ 29,909
Issuance of common stock under registered direct offering, net of offering costs, Shares						4,285,710
Exercise of stock options	4						4
Exercise of stock options, Shares				1,458
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,044						1,044
Other comprehensive income (loss)	42									42
Net loss	(8,991)										(8,991)
Balance at Mar. 31, 2021	91,880			$ 2			172,049			(255)	(79,916)
Balance, Shares at Mar. 31, 2021				29,040,270
Balance at Dec. 31, 2020	69,854			$ 2			141,074			(297)	(70,925)
Balance, Shares at Dec. 31, 2020				24,753,102
Other comprehensive income (loss)	88
Net loss	(18,149)
Balance at Jun. 30, 2021	84,773			$ 2			174,054			(209)	(89,074)
Balance, Shares at Jun. 30, 2021				29,382,806
Balance at Mar. 31, 2021	91,880			$ 2			172,049			(255)	(79,916)
Balance, Shares at Mar. 31, 2021				29,040,270
Issuance of common stock under employee stock purchase plan	127						127
Issuance of common stock under employee stock purchase plan, Shares				48,966
Exercise of stock options	796						796
Exercise of stock options, Shares				293,570
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,064						1,064
Other comprehensive income (loss)	46									46
Net loss	(9,158)										(9,158)
Balance at Jun. 30, 2021	84,773			$ 2			174,054			(209)	(89,074)
Balance, Shares at Jun. 30, 2021				29,382,806
Balance at Dec. 31, 2021	66,505			$ 2			176,618			(138)	(109,977)
Balance, Shares at Dec. 31, 2021				29,455,668
Issuance of common stock Bioniz acquisition		$ 22,542			$ 1			$ 22,541
Issuance of common stock, Bioniz acquisition					4,820,230
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,298						1,298
Other comprehensive income (loss)	(316)									(316)
Net loss	(37,417)										(37,417)
Balance at Mar. 31, 2022	52,630			$ 3			200,475			(454)	(147,394)
Balance, Shares at Mar. 31, 2022				34,275,898
Balance at Dec. 31, 2021	66,505			$ 2			176,618			(138)	(109,977)
Balance, Shares at Dec. 31, 2021				29,455,668
Other comprehensive income (loss)	(11)
Net loss	(51,546)
Balance at Jun. 30, 2022	40,267			$ 3			201,936			(149)	(161,523)
Balance, Shares at Jun. 30, 2022				34,352,084
Balance at Mar. 31, 2022	52,630			$ 3			200,475			(454)	(147,394)
Balance, Shares at Mar. 31, 2022				34,275,898
Issuance of common stock under employee stock purchase plan	141						141
Issuance of common stock under employee stock purchase plan, Shares				76,186
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,302						1,302
Other comprehensive income (loss)	305									305
Net loss	(14,129)										(14,129)
Balance at Jun. 30, 2022	$ 40,267			$ 3			$ 201,936			$ (149)	$ (161,523)
Balance, Shares at Jun. 30, 2022				34,352,084